Search

Adolescents and young adults (AYA)

Spotlight on AYAAdolescents and young adults (AYA) with hematologic diseases are a unique group with special characteristics and needs. In recent years, the challenges related to the management of AYA (particularly in relation to cancer) have increasingly been recognized.

Read more

Regulatory affairs & scientific relations

EHA’s regulatory work: European Medicines AgencyMost of EHA’s regulatory work entails collaboration with the European Medicines Agency (EMA).

Read more

Alliances & partnerships

EHA's approach to policy and regulatory affairs involves collaboration across medical professions and disciplines.

Read more

Scientific networks

Specialized Working Groups (SWGs)In order to cover the full hematology field, EHA Specialized Working Groups (SWGs) are divided in two groups: disease-oriented and overarching SWGs.

Read more

EHA Taskforce on Diversity, Equity, and Inclusion

The Diversity, Equity, and Inclusion Taskforce has a mandate from the EHA Board to develop a policy on Diversity, Equity, and Inclusion that will be the blueprint for:

Initiating and implementing activities to empower underrepresented groups.

Read more

Publications

Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry
Aiello TF, Salmanton-Garcia J, Marchesi F, et al. Haematologica. 2024 Aug 1;109(8):2693-2700.

Read more

Addressing immunoglobulin shortages: EHA and EBA’s strategic recommendations at the EMA

In recent years, shortages of immunoglobulins (Ig) have become a growing concern in the European Union (EU). Since 2018, the European Medicines Agency (EMA)—the EU agency that evaluates and supervises medicines—has received an increasing number of shortage reports.

Read more

EHA-GBMTA-AHA Hematology Tutorial

EHA is joining the Georgian Association for Blood and Bone Marrow Transplantation (GBMTA) and Armenian Hematology Association (AHA) to organize the EHA-GBMTA-AHA Hematology Tutorial on New Aspects in Diagnostic Choices and Treatment Options of Hematological Malignancies.

Read more